alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.
about
Treatment of Aggressive ADHD in Children and Adolescents: Conceptualization and Treatment of Comorbid Behavior DisordersOverdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and ManagementThe role of neuromodulators in selective attentionPrevention of serious conduct problems in youth with attention deficit/hyperactivity disorderProfile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorderVentral striatal noradrenergic mechanisms contribute to sensorimotor gating deficits induced by amphetamine.Increased cortisol after stress is associated with variability in response time in ADHD children.Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.Neurobiological substrates of Tourette's disorderMethylphenidate and the juvenile brain: enhancement of attention at the expense of cortical plasticity?Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortexMorphological abnormalities of the thalamus in youths with attention deficit hyperactivity disorder.Impact of acute guanfacine administration on stress and cue reactivity in cocaine-dependent individuals.Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates.The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders.High prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance networkModulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonistsWhere to with treatment for ADHD?Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control.An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents.Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo.Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.Dopamine vs noradrenaline: inverted-U effects and ADHD theories.Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis.Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders.Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.A review of the use of clonidine as a sleep aid in the child and adolescent population.Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial.Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.Adult ADHD: A new disease?Neonatal domoic acid alters in vivo binding of [(11)C]yohimbine to α2-adrenoceptors in adult rat brain.Pharmacokinetics and pharmacodynamics of guanfacine extended release in adolescents aged 13-17 years with attention-deficit/hyperactivity disorder.On the improvement of inhibitory response control and visuospatial attention by indirect and direct adrenoceptor agonists.Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism.Examination of reinforcement magnitude on the pharmacological disruption of fixed-ratio performance.
P2860
Q22241212-73F92B6D-01A0-43E6-B9BD-60DD9A6DB1BCQ22252568-A2809CF6-D986-4B39-9D97-F739C27A74EBQ26852620-879CCF39-8B4A-4AD7-9580-4FCFB667FE6AQ27025450-B9A71F25-D9BE-4933-87B7-D2F3578E2910Q27692647-29C67080-BAD9-4FA5-ABAF-55B6086B655EQ30475702-2A3DD6B0-BCC5-4955-BFA1-DBC1D124FFF9Q33670526-10429E15-7AEF-4EEA-BCBE-4D1538B6E297Q33819957-863A7247-8094-4AAA-A7CF-AFD07058E40BQ34135110-1184E213-848E-4DFB-AD5A-F359D0A5A31DQ34375450-021E1545-58A8-493E-8C13-5B87510823E4Q34381331-562F344F-C4C8-4E18-B394-D05ECDECFC13Q34803788-99A72411-D532-4794-8876-B3055978E4B4Q35106990-18C93907-4297-4199-8B0C-4C3FA53C4F94Q35226150-6EA4C211-FF80-453A-9C19-EE38F620BD85Q35589965-FEB4D346-AD47-4752-A920-074FA92E6115Q35619221-F5A0AE7D-6808-4A3B-999B-1B40193D2E32Q35644004-12FC6072-4120-48AD-8316-7B79121E1F4AQ35903241-816E6D68-0234-4B46-A009-04BAD9B0A4E6Q36446854-789CD605-3ACD-4A71-9624-E02D1905995AQ36595020-2F97B675-4C75-4D64-83AF-46B64DC1269CQ36853121-D19DEC41-EAB3-4356-B9AC-3BAAB9010D8FQ37091243-62A8AEF6-C836-42D9-B0B1-7259871CBA70Q37096227-691D22FB-2492-42B7-BCF6-464965710C1EQ37372629-77D58718-E5AF-48A0-B0EE-9A8D9696A463Q37542382-ADF7825A-AD86-4D21-A981-B98C7EFB88DEQ37589039-F3BFB851-F923-49A7-B5FB-FAF4D58B741DQ37598192-9976FA6D-CFE1-41F5-8A50-CC88E0F92B69Q37787239-70599017-87B7-4D8F-8175-B8BEC6153318Q37791316-B37CAD8A-3EAA-454D-ACB7-CC394CE18A24Q38011640-2BD56151-8F1F-489B-8C1F-E54F2AD31B86Q38060572-C54C79F8-902B-463D-B8FE-B35E9E69C127Q38136615-B668DE25-0E64-4DD3-8FE9-9D20BCE6E7CBQ38381196-9AEDF228-D773-4A6D-BE16-BB594FA643CFQ38395974-6A703691-45D6-4A0E-90FD-CCCE1D7491BFQ38799949-ABA838C6-D50A-4CD6-85A3-8F07B4FE4118Q39456703-5B381697-00B2-46E0-8EBB-E35920C4EBA5Q39809992-8E96CA56-267F-457A-A24C-07B0664D0DF1Q40086274-1B97B50A-DDA4-419F-A4A0-6612AAC1E2CCQ40307940-CED4C05F-25C2-4AB9-8904-82D3795C5728Q40623165-C891D50D-069F-411C-9109-C43405EE74CB
P2860
alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
alpha2-Adrenergic receptor ago ...... erging concepts from new data.
@ast
alpha2-Adrenergic receptor ago ...... erging concepts from new data.
@en
type
label
alpha2-Adrenergic receptor ago ...... erging concepts from new data.
@ast
alpha2-Adrenergic receptor ago ...... erging concepts from new data.
@en
prefLabel
alpha2-Adrenergic receptor ago ...... erging concepts from new data.
@ast
alpha2-Adrenergic receptor ago ...... erging concepts from new data.
@en
P356
P1476
alpha2-Adrenergic receptor ago ...... erging concepts from new data.
@en
P2093
Amy F Arnsten
Robert L Findling
P304
P356
10.1089/CAP.2006.0098
P577
2007-08-01T00:00:00Z